Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 01:18 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Early Alirocumab to Reduce LDL-C in Myocardial Infarction
NCT03750760 · Imperial College London · PHASE4 · withdrawn · last registry update 2019-06-13 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Changes in funding decision” | – | Registry record, Imperial College London |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PCSK9 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-05-18Results posted on the registry: The Medicines Company, ALN-PCSSC + Standard of Care (NCT02963311)
- 2020-05-01Results posted on the registry: Regeneron Pharmaceuticals, Placebo + Alirocumab (NCT02326220)
- 2020-04-24Also stopped (terminated): Medical University of Graz, a drug against PCSK9 (NCT03559309)
- 2020-04-21Also stopped (terminated): University of Utah, Alirocumab + Placebo (NCT03507374)
- 2020-04-03Results posted on the registry: Esperion Therapeutics, Inc., bempedoic acid 180mg + evolocumab (NCT03193047)
- 2020-03-30Results posted on the registry: Sanofi, ALIROCUMAB SAR236553 (REGN727) + placebo (for injection training only) (NCT02476006)
- 2019-12-06Also stopped (withdrawn): ECRI bv, Evolocumab (NCT03851263)
- 2019-09-30Results posted on the registry: Sanofi, Alirocumab + Placebo for alirocumab (NCT02715726)
- 2019-09-09Results posted on the registry: Sanofi, Alirocumab SAR236553 + Atorvastatin (NCT03415178)
- 2019-09-09Results posted on the registry: Sanofi, Alirocumab SAR236553 + Atorvastatin (NCT02984982)
- 2019-09-06Results posted on the registry: Virginia Commonwealth University, alirocumab + placebo (NCT02938949)
- 2019-09-06Results posted on the registry: Sanofi, alirocumab SAR236553 (REGN727) + statins (NCT02890992)
- 2019-07-26Phase 3 first posted: LIB Therapeutics LLC, lerodalcibep + evolocumab (NCT04034485)
- 2019-07-10Results posted on the registry: Amgen, Evolocumab (NCT01439880)
- 2019-06-19Results posted on the registry: University of California, San Francisco, Bococizumab + Placebo (NCT02524106)
- 2019-06-19Also stopped (terminated): University of California, San Francisco, Bococizumab + Placebo (NCT02524106)
- 2019-06-11Results posted on the registry: Amgen, Evolocumab + Standard of Care (NCT01854918)
- 2019-05-31Results posted on the registry: Pfizer, Bococizumab (PF-04950615; RN316) + Bococizumab (PF-04950615; RN316) (NCT02043301)
- 2019-05-17Results posted on the registry: The Medicines Company, ALN-PCSSC + Normal Saline (NCT02597127)
- 2019-05-01Also stopped (terminated): Pfizer, bococizumab (PF-04950615) + Placebo (NCT01975389)
- 2019-04-23Results posted on the registry: Amgen, Evolocumab + Placebo (NCT02729025)
- 2019-03-19Results posted on the registry: Amgen, Evolocumab (NCT02304484)
- 2019-03-18Results posted on the registry: Sanofi, Alirocumab + Placebo (NCT01663402)
- 2019-03-13Phase 3 first posted: Amgen, Evolocumab + Placebo (NCT03872401)
- 2019-02-25Results posted on the registry: Eli Lilly and Company, LY3015014 + Placebo (NCT01671085)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision